Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Norris Medicines Ltd held its 34th AGM on September 29, 2025, via video conferencing from 3:30 PM to 3:54 PM, with 34 members present. Mr. Vimal D. Shah chaired the meeting and CFO Mr. Iqubal Patel managed the proceedings. The meeting covered ordinary business (adoption of FY25 audited financials and re-appointment of Mr. Praveen J. Bafna as director) and seven special business items. Key special resolutions included a revision in the managerial remuneration of Executive Director Mr. Vimal D. Shah, an increase in the company's borrowing limits, authorization to sell or dispose of the company's undertaking, and enhancement of lending/investment limits under Section 186 of the Companies Act. Ms. Sathya Venkatachalam was proposed as a new Non-Executive Independent Director, and M/s HSPN & Associates, LLP was proposed as Secretarial Auditor. E-voting ran from September 26 to September 28, 2025, and the consolidated voting results will be announced within 2 working days.
No immediate share-price trigger, but the special resolutions on higher borrowing limits, possible sale of the company's undertaking, and revision in executive director remuneration are material items that, once voted on, will shape the company's capital structure and future direction. Shareholders should watch for the e-voting results and scrutinizer's report, expected within two working days.